Biologic agents are currently regarded as a highly efficacious systemic treatment for moderate to severe psoriasis. However, their use in patients with a history of malignancy or an increased risk of cancer is not recommended. The current recommendations are based on several case reports and observational studies, as well as data from randomized, controlled trials, associating these medications with tumorigenic properties. Furthermore, some reports describe malignancies arising de novo in patients using biologic agents. Psoriasis patients are at an increased risk of lymphoproliferative diseases and nonmelanoma skin cancers because of the inflammatory nature of the disease. A blockade of tumor necrosis factor-alpha (TNF-α) reduces inflammation but also may enhance tumor proliferation. Trials have not shown a significant increase in the risk of malignancy, with the exceptions of lymphoma and nonmelanoma skin cancers, with the use of TNF blockers. However, any risk may be unacceptable in a patient with a history or elevated risk of cancer. Ustekinumab acts on a different inflammatory pathway and may have a different profile regarding the risk of malignancy. A comprehensive review of the literature shows some consensus that relative contraindications are active malignancies and malignancies within the past 5 years. There is debate about nonmelanoma skin cancers and melanoma, but it seems prudent to use biologics more cautiously in a patient with a history of aggressive skin cancer, a high risk of recurrent skin cancer, or a history of extreme ultraviolet exposure. Additionally, certain combinations of immunosuppressive therapies, such as purine analogs, with biologics may lead to unacceptable risks of malignancy. Some subgroups, such as patients with chronic obstructive pulmonary disease, are already predisposed to lung cancer because of a significant smoking history; these patients require closer monitoring during biologic therapy. As the biologics are in use longer for psoriasis, more data on the long-term safety of these therapeutics will be available.
PatelR.V., ClarkL.N., LebwohlM., WeinbergJ.M.Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol.2009; 60(6): 1001–17.
2.
MenterA., GottliebA., FeldmanS.R.Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1: Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol.2008; 58: 826–50.
3.
BeralV., New tonR.Over view of the epidemiology of immunodeficiency-associated cancers. J Natl Cancer Inst Monogr.1998; 23: 1–6.
4.
GuptaA.K., CardellaC.J., HabermanH.F.Cutaneous malignant neoplasms in patients with renal transplants. Arch Dermatol.1986; 122: 1288–93.
5.
HochbergM.C., LebwohlM.G., PlevyS.E., HobbsK.F., YocumD.E.The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum.2005; 34: 819–36.
6.
Hannuksela-SvahnA., PukkalaE., LaaraE., PoikolainenK., KarvonenJ.Psoriasis, its treatment and cancer in a cohort of Finnish patients. J Invest Dermatol.2000; 114: 587–90.
7.
MellemkjaerL., LinetM.S., GirdleyG.Rheumatoid arthritis and cancer risk. Eur J Cancer.1996; 32: 1753–57.
8.
American College of Rheumatology Hotline. FDA Meeting March 2003: update on the safety of new drugs for rheumatoid arthritis. Part I: The risk of lymphoma with rheumatoid arthritis (RA) and TNF inhibitors. Available at: http://rheumatology.org/publications/hotline/0303tnfl.asp. Accessed April 2009.
9.
BaecklundE., EkbomA., SparenP.Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. Ann Rheum Dis.1998; 317(7152): 180–1.
10.
MargolisD., BilkerW., HennessyS., VittorioC., SantannaJ., StromB.L.The risk of malignancy associated with psoriasis. Arch Dermatol.2001; 137: 778–83.
11.
GelfandJ.M., BerlinJ., Van VoorheesA., MargolisD.J.Lymphoma rates are low but increased in patients with psoriasis. Arch Dermatol.2003; 139: 1425–29.
12.
GelfandJ.M., ShinD.B., NeimannA.L., WangX., MargolisD.J., TroxelA.B.The risk of lymphoma in patients with psoriasis. J Invest Dermatol.2006; 126: 2194–201.
PaulC.F., HoV.C., McGeownC.Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol.2003; 120: 211–6.
15.
BurmesterG.R., MeaseP.J., DijkmansB.A.Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis.2009; 68: 1863–9.
16.
BongartzT., WarrenF.C., MinesD., MattesonE.L., AbramsK.R., SuttonA.J.Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomized controlled trials. Ann Rheum Dis.2009; 68: 1177–83.
BrownS.L., GreeneM.H., GershonS.K., EdwardsE.T., BraunM.M.T.Tumor necrosis factor antagonist therapy and lymphoma development twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum.2002; 46: 3151–8.
19.
GirardC., GuillotB., BessisD.Gastric MALT lymphoma in a patient receiving infliximab for psoriasis. Br J Dermatol.2008; 159(2): 497–8.
20.
Abbott, Inc.Prescribing information for HUMIRA. Available at: http://www.humirapro.com/. Accessed August 2011.
MenterA., ReichK., GottliebA.Adverse events in infliximab-treated patients compared with general and psoriasis populations. J Drugs Dermatol.2008; 7(12): 1137–46.
24.
BongartzT., SuttonA.J., SweetingM.J., BuchanI., MattesonE.L., MontoriV.Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA.2006; 295: 2275–85.
25.
DixonW., SilmanA.Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz, et al. Arthritis Res Ther.2006; 8(5): 111.
26.
OkadaS.K., SiegelJ.N.Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA.2006; 296(18): 2201–2202; author reply 2203–4.
27.
AsklingJ., BaeklandE., GranathF.Anti-TNF therapy in PA and risk of malignant lymphomas: relative risks and time-trends in the Swedish Biologics Register. Ann Rheum Dis.2008: 68(5): 648–53.
28.
CostenbaderK.H., GlassR., CuiJ., ShadickN.Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA.2006; 296(18): 2201; author reply 2203–4.
29.
DommaschE.D., AbuabaraK., ShinD.B., NguyenJ., TroxelA.B., GelfandJ.M.The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol.2011; 64(6): 1035–50.
30.
GeborekP., BladstromA., TuressonC.Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with increased risk of lymphomas. Ann Rheum Dis.2005; 64(5): 699–703.
31.
AsklingJ., ForedC.M., BaecklundE.Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis.2005; 64(10): 1414–20.
32.
WolfeF., MichaudK.Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum.2004; 50: 1740–51.
33.
WolfeF., MichaudK.Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum.2007; 56: 2886–95.
34.
SetoguchiS., SolomonD.H., WeinblattM.E.Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum.2006; 54(9): 2757–64.
35.
MackeyA.C., GreenL., LiangL.Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr.2007; 44: 265–7.
36.
ThayuM., MarkowitzJ.E., MamulaP.Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn's disease. J Pediatr Gastroenterol Nutr.2005; 40: 220–2.
37.
ZeidanA., ShamR., ShapiroJ.Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy. Leuk Lymphoma.2007; 48: 1410–3.
38.
BeyerM., SteinhoffM., AnagnostopoulosI., AssafC., SterryW.Hepatosplenic T-cell lymphomas and therapy with TNF-alpha-blocking biologics: a risk for psoriasis patients?J Dtsch Dermatol Ges.2009; 7(3): 191–4.
39.
AdamsA.E., ZwickerJ., CurielC.Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. J Am Acad Dermatol.2004; 51: 660–2.
40.
MaheV., DescampsM., GrossinS., FraitagB., CrickxB.CD30+ T-cell lymphoma in a patient with psoriasis treated with cyclosporin and infliximab. Br J Dermatol.2003; 149: 170–3.
41.
PielopJ.A., JonesD., DuvicM.Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatment. Int J Dermatol.2001; 40: 505–11.
42.
CorazzaM., ZampinoM.R., MontanariA., AltieriE., VirgiliA.Primary cutaneous CD30+ large T-cell lymphoma in a patient with psoriasis treated with cyclosporine. Dermatology2003; 206: 330–3.
MarcilI., SternR.S.Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet2001; 358: 1042–5.
45.
AsklingJ., ForedM., BrandtL.Risks of solid cancers in patients with rheumatoid arthritis and following treatment with TNF-antagonists. Ann Rheum Dis.2005; 64: 1421–6.
46.
LyL., CzarneckiD.The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis. Br J Dermatol.2007; 157(5): 1076–8.
47.
SmithK.J., SkeltonH.Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis starting tumor necrosis factor alpha receptor IgG1–Fc fusion complex therapy. J Am Acad Dermatol.2001; 49: 953–6.
48.
ComteC., GuilhouJ.J., GuillotB.Rapid onset and fatal outcome of two squamous cell carcinomas of the genitalia in a patient treated with etanercept for cutaneous psoriasis. Dermatology.2008; 217: 284–5.
49.
FrentzG., OlsenJ.H.Malignant tumors and psoriasis: a follow-up study. Br J Dermatol.1999; 140: 237–42.
50.
SternR.S., LairdN.The carcinogenic risk of treatments for severe psoriasis: photochemistry follow-up study. Cancer.1994; 73: 2759–64.
51.
LeonardiC.L., TothD., CatherJ.C.A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology.2006; 213: 204–14.
52.
FryrearR.S., WigginsA.K., SanguezaO., YosipovitchG.Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy. J Am Acad Dermatol.2004; 51: 1026.
53.
LebwohlM., BlumR., BerkowitzE.No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol.2005; 141: 861–4.
54.
EsserA.C., AbrilA., FayneS., DoyleJ.A.Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol.2004; 50: 575–7.
55.
FulchieroG.J.Jr, SalvaggioH., DrabickJ.J.Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol.2007; 56: S65–S67.
56.
KowalzickL., EickenscheidtL., KomarM., SchaarschmidtE.[Long term treatment of psoriasis with TNF-alpha antagonists: occurrence of malignant melanoma]. Hautarzt.2009; 60(8): 655–7.
57.
RennardS.I., FogartyC., KelsenS.The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care.2007; 175(9): 926.
58.
KhuranaR., WolfR., BerneyS., Risk of development of lung cancer is increased in patients with rheumatoid arthritis. J Rheumatol.2008; 35(9): 1704–8.
59.
LeesC.W., IronsideJ., WallaceW.A.Resolution of non-small-cell lung cancer after withdrawal of anti-TNF therapy. N Engl J Med.2008; 359(3): 320–1.
60.
StoneJ.H., HolbrookJ.T., MarriotM.A.Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum.2006; 54: 1608–18.
61.
BaklandG., NossentH.Acute myelogenous leukaemia following etanercept therapy. Rheumatology.2003; 42: 900–1.
62.
BachmeyerC., ThioliereB., KhosrotehraniK., CattanE.Acute myelogenous leukemia in a patient receiving etanercept for psoriasis. J Am Acad Dermatol.2006; 59: 69.
63.
AlcaínG., AndradeR.J., Queipo de LlanoM.P.Acute leukemia after infliximab therapy. Am J Gastroenterol.2003; 98(11): 2577.
64.
NairB., RavalG., MehtaP.TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol.2007; 82: 1022–4.
65.
BroussaisF., KawashimaM., MarotteH., MiossecP.Chronic myeloid leukaemia and tuberculosis in a patient with rheumatoid arthritis treated with infliximab. Ann Rheum Dis.2005; 64(3): 509–510.
66.
MeyboomR.H., StarK., BateJ., SavageR., EdwardsI.R.TNF-alpha inhibitors and leukaemia: international pharmacovigilance reports. Drug Saf.2008; 31(5): 445–447.
67.
BoehnckeW.H., BrasieR.A., BarkerJ.; European Dermatology Expert Group. Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus. J Eur Acad Dermatol Venereol.2006; 20(8): 988–98.
HamiltonT., MenterA., CaroI.Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial. Drug Safety.2008; 31(8): 715–26.
LebwohlM., ChristophersE., LangleyR.An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol.2003; 139: 719–27.
77.
KruegerG.G., PappK.A., StoughD.B.A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol.2002; 47: 821–33.
78.
GoffeB., PappK., GrattonD.An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther.2005; 27(12): 1912–21.
79.
PappK.A., LangleyR.G., LebwohlM.; PHOENIX 2 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet.2008: 371(9625): 1675–84.
80.
LeonardiC.L., KimballA.B., PappK.A.; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet.2008; 371(9625): 1665–74.
81.
SegalB.M., ConstantinescuC.S., RaychaudhuriA., KimL., Fidelus-GortR., KasperLH, UstekinumabM.S.Investigators. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol.2008; 7(9): 796–804.
82.
SandbornW.J., FeaganB.G., FedorakR.N.; Ustekinumab Crohn's Disease Study Group. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology.2008; 135(4): 1130–41.
83.
GottliebA., MenterA., MendelsohnA.Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet.2009; 373(9664): 633–40.
84.
TanJ.Y., LiS., YangK.Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: a meta-analysisJ Dermatolog Treat.2010; [E-pub ahead of print].
85.
LebwohlM., LeonardiC., GriffithsC.E.M.Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Dermatol.2011; Sept 17 [E-pub ahead of print].
86.
ChongB.F., WongH.K.Treatment of psoriasis with etanercept in a patient with a history of primary B-cell lymphoma. Clin Exp Dermatol.2009; 34(3) e11–e13.
87.
SmithC.H., AnsteyA.V., BarkerJ.N.British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol.2005; 153: 486–97.
88.
PappK.A.Monitoring biologics for the treatment of psoriasis. Clin Dermatol.2008; 26(5): 515–21.
89.
TzuJ., KerdelF.From conventional to cutting edge: the new era of biologics in treatment of psoriasisDermatol Ther.2008; 21(2): 131–41.
90.
LimaX.T., SeidlerE.M., LimaH.C., KimballA.B.Long-term safety of biologics in dermatology. Dermatol Ther.2009; 22(1): 2–21.
91.
KruegerG.G., GottliebA.B., SterryW., KormanN., Van De KerkhofP.A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis. J Dermatolog Treat.2008; 19(3): 146–55.
92.
StebbinsW.G., LebwohlM.G.Biologics in combination with nonbiologics: efficacy and safety. Dermatol Ther.2004; 17(5): 432–40.
